MY160732A - A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol - Google Patents
A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycolInfo
- Publication number
- MY160732A MY160732A MYPI2013000217A MYPI2013000217A MY160732A MY 160732 A MY160732 A MY 160732A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY 160732 A MY160732 A MY 160732A
- Authority
- MY
- Malaysia
- Prior art keywords
- stimulating factor
- granulocyte colony
- csf
- polyethylene glycol
- conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
THE PRESENT INVENTION RELATES TO PHARMACEUTICALS AND MEDICINE, NAMELY, TO NEW PHYSIOLOGICALLY ACTIVE CONJUGATES OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) WITH THE GENERAL FORMULA: THE INVENTION IS ALSO RELATED TO MEDICINES CONTAINING THE CLAIMED CONJUGATE OF FORMULA (I), PHARMACEUTICAL COMPOSITIONS, THE USE OF CONJUGATE OF FORMULA (I) FOR DRUGS AND MEDICINES WITH GRANULOCYTE COLONY STIMULATING FACTOR AS AN ACTIVE INGREDIENT, APPROACHES TO PREVENT AND/ OR TREAT NEUTROPENIA, THE CONTAINER THAT COMPRISES PHARMACEUTICAL COMPOSITION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010133875/10A RU2446173C1 (en) | 2010-08-13 | 2010-08-13 | New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent |
Publications (1)
Publication Number | Publication Date |
---|---|
MY160732A true MY160732A (en) | 2017-03-15 |
Family
ID=45567857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2013000217A MY160732A (en) | 2010-08-13 | 2011-07-19 | A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol |
Country Status (17)
Country | Link |
---|---|
KR (1) | KR101549457B1 (en) |
CN (1) | CN103140499B (en) |
CL (1) | CL2013000400A1 (en) |
CO (1) | CO6670557A2 (en) |
CR (1) | CR20130020A (en) |
CU (1) | CU24139B1 (en) |
DO (1) | DOP2013000003A (en) |
EA (1) | EA019043B1 (en) |
EC (1) | ECSP13012399A (en) |
MA (1) | MA34525B1 (en) |
MY (1) | MY160732A (en) |
NI (1) | NI201300007A (en) |
PE (1) | PE20131085A1 (en) |
RS (1) | RS20130094A1 (en) |
RU (1) | RU2446173C1 (en) |
SG (1) | SG187572A1 (en) |
WO (1) | WO2012021088A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012110057A1 (en) | 2011-02-15 | 2012-08-23 | Chemisches Institut Schaefer Ag | Cefuroxime safety kit |
KR102083046B1 (en) | 2012-06-07 | 2020-02-28 | 칠드런'스 하스피틀 로스 앤젤레스 | Methods for treating neutropenia using retinoid agonists |
CN103908427B (en) * | 2013-01-05 | 2014-12-17 | 石药集团百克(山东)生物制药有限公司 | Polyethylene glycol modified rhG-CSF injection and preparation method thereof |
RU2535002C2 (en) * | 2013-04-04 | 2014-12-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure |
EP3107533A4 (en) | 2014-02-18 | 2017-10-18 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
PE20170769A1 (en) | 2014-07-14 | 2017-07-04 | Gennova Biopharmaceuticals Ltd | NOVEL PROCEDURE FOR PURIFICATION OF RHU-GCSF |
IL247369B (en) * | 2016-08-18 | 2018-08-30 | B G Negev Tech And Applications Ltd | Modified m-csf polypeptides and use thereof |
KR102020995B1 (en) * | 2017-10-30 | 2019-09-16 | 한국코러스 주식회사 | A method of preparing gcsf and polyol_conjugated conjugates with high yield |
KR20220154214A (en) * | 2020-03-17 | 2022-11-21 | 드럭리큐어 에이피에스 | Liquid formulation of GM-CSF for inhalation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE135370T1 (en) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
KR20040083268A (en) * | 2003-03-21 | 2004-10-01 | 한미약품 주식회사 | Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof |
RU2278870C2 (en) * | 2004-08-30 | 2006-06-27 | Закрытое Акционерное Общество "Биокад" | Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof |
WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
JP2009541333A (en) * | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | Modified ribonuclease |
-
2010
- 2010-08-13 RU RU2010133875/10A patent/RU2446173C1/en active
-
2011
- 2011-07-19 MA MA35731A patent/MA34525B1/en unknown
- 2011-07-19 WO PCT/RU2011/000532 patent/WO2012021088A1/en active Application Filing
- 2011-07-19 PE PE2013000083A patent/PE20131085A1/en not_active Application Discontinuation
- 2011-07-19 CN CN201180044089.6A patent/CN103140499B/en not_active Expired - Fee Related
- 2011-07-19 MY MYPI2013000217A patent/MY160732A/en unknown
- 2011-07-19 SG SG2013004544A patent/SG187572A1/en unknown
- 2011-07-19 KR KR1020137001860A patent/KR101549457B1/en not_active IP Right Cessation
- 2011-07-19 CU CU20130012A patent/CU24139B1/en unknown
- 2011-07-19 RS RS20130094A patent/RS20130094A1/en unknown
- 2011-08-01 EA EA201101035A patent/EA019043B1/en not_active IP Right Cessation
-
2013
- 2013-01-04 DO DO2013000003A patent/DOP2013000003A/en unknown
- 2013-01-18 NI NI201300007A patent/NI201300007A/en unknown
- 2013-01-18 CO CO13009151A patent/CO6670557A2/en unknown
- 2013-01-18 CR CR20130020A patent/CR20130020A/en unknown
- 2013-01-18 EC ECSP13012399 patent/ECSP13012399A/en unknown
- 2013-02-08 CL CL2013000400A patent/CL2013000400A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20131085A1 (en) | 2013-10-10 |
CO6670557A2 (en) | 2013-05-15 |
CL2013000400A1 (en) | 2013-07-26 |
MA34525B1 (en) | 2013-09-02 |
KR20130043167A (en) | 2013-04-29 |
CR20130020A (en) | 2013-02-20 |
WO2012021088A1 (en) | 2012-02-16 |
NI201300007A (en) | 2014-05-26 |
CN103140499A (en) | 2013-06-05 |
ECSP13012399A (en) | 2013-05-31 |
SG187572A1 (en) | 2013-03-28 |
CN103140499B (en) | 2014-12-17 |
KR101549457B1 (en) | 2015-09-02 |
EA019043B1 (en) | 2013-12-30 |
CU24139B1 (en) | 2015-12-23 |
RS20130094A1 (en) | 2013-08-30 |
EA201101035A1 (en) | 2012-02-28 |
RU2446173C1 (en) | 2012-03-27 |
CU20130012A7 (en) | 2013-04-19 |
DOP2013000003A (en) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY160732A (en) | A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol | |
NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
BR112013003045A2 (en) | compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration | |
EA201690102A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
MX2014009757A (en) | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
MX2012007410A (en) | Novel antiviral compounds. | |
MX2011008634A (en) | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
MY188598A (en) | Dexmedetomidine premix formulation | |
MY149731A (en) | Compounds | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
MX2009013501A (en) | Piperidine compounds and uses thereof. | |
IN2015DN03854A (en) | ||
PH12014502619A1 (en) | Novel dosage and formulation | |
HRP20140591T1 (en) | Improved medicinal compositions comprising buprenorphine and nalmefene | |
EA201300857A1 (en) | PYRAZOLES AS AN ANTAGONISTS CRTH2 | |
EP2682129A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous | |
WO2011058245A8 (en) | Novel mannopyranoside derivatives with anticancer activity | |
MX2021014830A (en) | CONJUGATES OF <i>Ï</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS. | |
CY1115600T1 (en) | Piperazines as Anthelmintic Agents | |
BR112012020415A2 (en) | pharmaceutical composition for the prevention or treatment of osteoarthritis | |
MX2015014905A (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS. | |
PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
WO2015027669A3 (en) | Phenyl-substituted compound, pharmaceutical composition and uses thereof | |
UA97076C2 (en) | Anti-inflammatory ointment based on sulfanilamide |